Description

Exelixis Is Not Just Cabozantinib — Zanzalintinib Could Open A New Oncology Chapter!

Exelixis reported its second quarter 2026 financial results demonstrating continued execution of its multi-franchise oncology strategy, anchored by the established cabozantinib (cabo) franchise and the advancing development of its next potential franchise, zanzalintinib (zanza). Total revenues for Q2 2026 were approximately $629 million, with cabozantinib net product revenues reaching $573 million, up 10% year-over-year in the U.S. and 13% globally. The cabozantinib franchise maintains its leadership position in renal cell carcinoma (RCC) as the top tyrosine kinase inhibitor (TKI) and TKI plus immuno-oncology (IO) combination, as well as in the second-line plus neuroendocrine tumor (NET) segment. Growth in NET has been modestly slower than initially projected due to the unique patient population and disease characteristics, including slower disease progression and less frequent treatment initiation.